论文部分内容阅读
目的:探讨曲妥珠单抗在治疗HER2阳性的转移性乳腺癌时,产生耐药性与CD44v6表达的相关性。方法:共66例HER2阳性转移性乳腺癌患者入组。接受曲妥珠单抗治疗的患者37例,其中18例获得了治疗前和治疗后转移性癌组织。采用免疫组化S-P法对治疗前、治疗后的不同乳腺组织进行CD44v6表达的研究。结果:CD44v6在经曲妥珠单抗治疗产生耐药的活检组织中阳性表达程度明显高于治疗前。结论:CD44v6的表达与曲妥珠单抗耐药相关。
Objective: To investigate the relationship between trastuzumab and CD44v6 expression in the treatment of HER2-positive metastatic breast cancer. Methods: A total of 66 patients with HER2 positive metastatic breast cancer were enrolled. Thirty-seven patients received trastuzumab, 18 of whom received metastatic cancer tissue before and after treatment. The immunohistochemical S-P method was used to study the expression of CD44v6 in different breast tissues before and after treatment. Results: The positive expression of CD44v6 in the biopsy tissues that had been resistant to trastuzumab was significantly higher than that before treatment. Conclusion: The expression of CD44v6 is correlated with trastuzumab resistance.